US approves Lilly/Daiichi's prasugrel with boxed warning on bleeding
This article was originally published in Scrip
Executive Summary
The US FDA has approved Lilly/Daiichi Sankyo's novel antiplatelet therapy Effient (prasugrel) to reduce the risk of thrombotic cardiovascular events, including stent thrombosis, in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention. The companies said they will launch the drug in the coming weeks.